The BioPharm Brief: HER2 Approvals, Deals, and Survival Data

Sep 01, 06:54 PM
Headliner
Share
Subscribe

Today’s BioPharm Brief covers a new first-line HER2 breast cancer approval in Europe, a $1.5 billion Roche deal, and new survival data for Ziihera in gastroesophageal cancer.

Share
Subscribe
Next
The BioPharm Brief: New Approval, Trial Halt, and Updated Vaccine
Top episodes
The BioPharm Brief: Early Design Risks, Oncology Signals, and a Biosimilars Power Move
by The BioPharm Brief
The BioPharm Brief: Cancer, Personalized
by The BioPharm Brief
The BioPharm Brief: What’s the Big Deal About Multispecific T-Cell Engagers in Cancer and Autoimmune Diseases?
by The BioPharm Brief